Roche loses money in Russia, says Chief Executive Severin Schwan

Published On 2022-03-29 03:30 GMT   |   Update On 2022-03-29 03:30 GMT

Zurich: Roche is "losing money in Russia", Chief Executive Severin Schwan said in an interview published on Tuesday, but remains committed to providing medication to patients there.

"We can't just withhold life-saving cancer drugs from Russian patients. There is international consensus that medicines are exempt from sanctions," Schwan told Swiss newspaper TagesAnzeiger, adding that prices being fixed in Russian roubles meant the pharmaceutical giant was currently losing money on Russian sales.

The statement echoed other pharmaceutical giants, who have said they will supply essential medicines in Russia but halt some other activities in response to Russia's invasion of Ukraine. 

Roche has 800 sales staff in Russia, he said.

Speaking about his upcoming exit from the board of big bank Credit Suisse, Schwan said he had already considered resigning a year ago but it had become opportune after a twin set of scandals hammered the bank last March.

The bank was now in "good hands" under new Chairman Axel Lehmann, the outgoing vice-chair said.

Asked whether larger Swiss rival UBS or a foreign bank might take over Credit Suisse since its share price had been battered, Schwan said he hoped the bank would remain independent.

"It would be a huge loss for Switzerland if there were only one major Swiss bank. That's why it's important that CS stabilises its business, rebuilds trust and seizes its opportunities," he said.

He said he would be willing to take on another board role in the future.

"In principle, I think it is feasible to sit on the board of a bank alongside my job as CEO at Roche," he said.

"The fact that I'm stepping down now doesn't mean that I don't think it's important for an active CEO to take on such a task. We need banks, they are like the oil in the gears. And for some things we need specifically Swiss banks."

Read also: Roche, Bristol Myers Squibb ink pact to advance personalised healthcare through digital pathology solutions

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News